Juno Therapeutics, Inc. (NASDAQ:JUNO) Director Anthony B. Evnin acquired 9,000 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were bought at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the transaction, the director now directly owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Juno Therapeutics, Inc. (NASDAQ:JUNO) traded up 2.00% during trading on Friday, reaching $27.52. The company had a trading volume of 435,755 shares. The stock has a 50 day moving average price of $23.95 and a 200-day moving average price of $22.12. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $43.76. The company’s market capitalization is $2.87 billion.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.01. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The firm had revenue of $19.30 million for the quarter, compared to analysts’ expectations of $16 million. During the same period last year, the firm earned ($0.78) EPS. The business’s quarterly revenue was up 96.9% on a year-over-year basis. On average, equities research analysts anticipate that Juno Therapeutics, Inc. will post ($2.99) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Anthony B. Evnin Purchases 9,000 Shares of Juno Therapeutics, Inc. (JUNO) Stock” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://transcriptdaily.com/2017/06/23/anthony-b-evnin-purchases-9000-shares-of-juno-therapeutics-inc-juno-stock.html.
A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in Juno Therapeutics by 31,399.7% in the first quarter. BlackRock Inc. now owns 4,183,793 shares of the biopharmaceutical company’s stock valued at $92,838,000 after buying an additional 4,170,511 shares during the period. Norges Bank purchased a new stake in Juno Therapeutics during the fourth quarter valued at about $13,993,000. State Street Corp increased its stake in Juno Therapeutics by 16.3% in the fourth quarter. State Street Corp now owns 3,415,744 shares of the biopharmaceutical company’s stock valued at $64,380,000 after buying an additional 478,044 shares during the period. First Trust Advisors LP increased its stake in Juno Therapeutics by 47.1% in the first quarter. First Trust Advisors LP now owns 1,377,667 shares of the biopharmaceutical company’s stock valued at $30,570,000 after buying an additional 440,984 shares during the period. Finally, BB Biotech AG increased its stake in Juno Therapeutics by 16.8% in the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock valued at $48,485,000 after buying an additional 315,000 shares during the period. 65.34% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently weighed in on JUNO. Wedbush reaffirmed a “neutral” rating and set a $24.00 price objective on shares of Juno Therapeutics in a research report on Friday, May 5th. FBR & Co cut their price objective on Juno Therapeutics from $30.00 to $29.00 and set a “mkt perform” rating on the stock in a research report on Friday, May 5th. Zacks Investment Research lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd. Vetr lowered Juno Therapeutics from a “strong-buy” rating to a “strong sell” rating and set a $22.32 price objective on the stock. in a research report on Wednesday, March 1st. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Juno Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $31.38.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.